RBBP8

Across TCGA pan-cancer cohorts, RBBP8 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated RBBP8 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher RBBP8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RBBP8 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

THYM, BRCA, and KIRP are the cancer types where RBBP8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
BRCA	OS	Median	All	0.736	0.924	.002	16	view →
KIRP	OS	Median	All	0.216	0.903	.002	12	view →
BLCA	DFS	Median	III,IV	1.000	0.268	.022	8	view →
THCA	DFS	Median	All	0.061	0.841	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	All	0.960	0.620	.020	6	view →
SKCM	DFS	Median	All	0.710	0.195	.022	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

RBBP8–THYM (OS)

Open the THYM breakdown →